FIELD: biotechnology.
SUBSTANCE: disclosed is an agent for inhibition of iron absorption by cells, containing an antibody which recognizes amino acids in positions 629–633 of the human transferrin receptor. Also disclosed is an agent for inhibiting binding between human transferrin and human transferrin receptor, which contains said antibody.
EFFECT: invention can be used for treating a disease or a symptom associated with excessive absorption of iron by cells.
11 cl, 5 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
| ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
| SHUTTLE FOR BLOOD-BRAIN BARRIER | 2019 |
|
RU2754794C2 |
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
